AQUA 22: BONE IMAGING AND SOFT TISSUE IMAGING AT THE TIME OF DIAGNOSIS OF METASTATIC CRPC

STEWARD

AMERICAN UROLOGICAL ASSOCIATION

DESCRIPTION

Percentage of patients who receive bone imaging and soft tissue imaging at the time of diagnosis of metastatic CRPC

TYPE

Process

DATA SOURCE

Electronic Health Records: AQUA Registry Data

NUMERATOR STATEMENT

Patients receiving bone imaging and soft tissue imaging (may include CT/PET) 30 days previous to or after the diagnosis of metastatic CRPC

DENOMINATOR STATEMENT

Patients with CRPC and metastatic CRPC

DENOMINATOR DETAILS

List Denominator Codes

DENOMINATOR EXCLUSIONS/EXCEPTIONs

RATIONALE

Patients with a diagnosis of metastatic CRPC should receive bone and soft tissue imaging. Visceral metastases portend a poor prognosis. They also suggest certain treatments should not be used (radium-223). As such, it is important to assess this for prognostic and therapeutic purposes at the time of initial metastatic CRPC diagnosis.

RISK ADJUSTMENT

No

INVERSE MEASURE

No

ALGORITHM

COPYRIGHT/DISCLAIMER

AMERICAN UROLOGICAL ASSOCIATION